DOCSLIB.ORG

Icnmdigital Speaker Disclosures 09.02.2020NG.Xlsx

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Icnmdigital Speaker Disclosures 09.02.2020NG.Xlsx Name Individual's Role(s) Name of Commercial Interest(s) Nature of Relationship(s) Scientific Session in Activity Abati, Elena Speaker Nothing to disclose Nothing to disclose Scientific Session 06 Alvarez Velasco, Rodrigo Speaker Nothing to disclose Nothing to disclose Scientific Session 09 Beeson, David Speaker 1) Programme Grant, Medical Research Council, UK 1) Receipt of grants/research supports Scientific Session 07 Benaviste, Olivier Speaker Nothing to disclose Nothing to disclose Scientific Session 01 Callaghan, Brian Speaker 1) NIDDK R01, VA Merit CSR&D, JDRF, AAN 1) Receipt of grants/research supports Scientific Session 05 2) Neurology editorial board 2) Reciept of honoraia or consultation fees 3) Dynamed consultant, medicolegal consultation including the 3) Other Vaccine Injury Compensation Program Chelban, Viorica Speaker Nothing to disclose Nothing to disclose Scientific Session 06 Djordjevic, Djurdja Speaker Nothing to disclose Nothing to disclose Scientific Session 06 Evoli, Amelia Speaker 1) UCB 1) Receipt of honoraria or consultation fees (member data monitoring Scientific Session 08 2) Grifols committee) 2) Receipt of Honararia or consulataion fees (Research award jury member) Exposito Escudero, Jesica Maria Speaker Nothing to disclose Nothing to disclose Scientific Session 12 Finkel, Richard Speaker 1) Avexis, Biogen, Capricor, Catebasis, Reveragen, Roche, 1) Receipt of grants/research supports Scientific Session 11 Scholar Rock 2) Reciept of honoraia or consultation fees 2) Avexis, Biogen, Caterasis, Roch, Neurogene 3) Spouse/partner 3) Licencing fees from patents: National Jewish Center, 4) Other support Children's Hospital of Philadelphia 4) Licensing fees rom Children's Hospital of Philadelphia, Royalty payments from Elseview Flanigan, Kevin Speaker 1) Sarepta Therapeutics, Audentes Therapeutic 1) Receipt of grants/research supports Scientific Session 01 2) 4D Molecular Therapeutics, Apic Bio 2) Reciept of honoraia or consultation fees Gilhus, Nils Erik Speaker 1) RaPharma, UCB, Argenx, Alexion, Octapharma 1) Reciept of honoraia or consultation fees Scientific Session 08 Howard, James Speaker 1) Alexion Pharmaceuticals, argenx BVBA, the Centers for 1) Receipt of grants/research supports Scientific Session 09 Disease Control and Prevention (Atlanta, GA, USA), the Muscular 2) Reciept of honoraia or consultation fees Dystrophy Association, the National Institutes of Health 3) Stock Shareholder (including the National Institute of Neurological Disorders and 4) Spouse/partner Stroke and the National Institute of Arthritis and 5) Other ‐ non financial support Musculoskeletal and Skin Diseases), Ra Pharmaceuticals 2) Alexion Pharmaceuticals, argenx BVBA, Ra Pharmaceuticals and Viela Bio Inc. 3) Johnson & Johnson, Pfizer 4) GSK 5) Alexion Pharmaceuticals, argenx BVBA, Ra Pharmaceuticals and Toleranzia Name Individual's Role(s) Name of Commercial Interest(s) Nature of Relationship(s) Scientific Session in Activity Laporte, Jocelyn Speaker Nothing to disclose Nothing to disclose Scientific Session 03 Lauria, Giuseppe Speaker Nothing to disclose Nothing to disclose Scientific Session 04 Llamusi, Beatriz Speaker Nothing to disclose Nothing to disclose Scientific Session 03 Querol, Luis Speaker 1) Fondo Investigaciones Sanitarias, Grifols, Roche, CIBERER 1) Receipt of grants/research supports Scientific Session 04 2) Grifols, Roche, Sanofi, Merck, Novatis, CSU, Alexion, Annexon, 2) Reciept of honoraia or consultation fees Johnson & Johnson 3) Participation in a company sponsored speaker's bureau 3) CSL Behring, Roche, Novaris, UCB, Merck Reilly, Mary Speaker 1) Ad hoc consultancy fees Alnylam, Akcea, Inflectis 1) Reciept of honoraia or consultation fees Scientific Session 05 Reyes Garrido, Virginia Speaker Nothing to disclose Nothing to disclose Scientific Session 12 Scaglioni, Dominic Speaker 1) Sarepta Therapeutics 1) Receipt of grants/research supports Scientific Session 03 Servais, Laurent Speaker 1) Roche, Avexis, Biogen 1) Receipt of grants/research supports Scientific Session 11 2) Roche, Avexis, Biogen, Cytokinetics 2) Reciept of honoraia or consultation fees Straub, Volker Speaker Nothing to disclose Nothing to disclose Scientific Session 02 Tannemaat, Martijn Speaker 1) Trial support from Argen‐X and Alexion (all reimbursements 1) Receipt of grants/research supports Scientific Session 09 received by the LUMC) Traynor, Bryan Speaker 1) Merck Inc & Microsoft Research 1) Receipt of grants/research supports Scientific Session 10 2) Other 2)Patent on the diagnostic use of C9orf72, support from The Myasthenia Gravis Foundation, the ALS foundation, CDC, the intramural research program of the NIH. Dr. Traynor is on the editorial board of JNNP, Neurobiology of Aging, and Jama Neurology. Van Den Berg , Leonard Speaker 1) U‐trail Utrecht 1) Receipt of grants/research supports Scientific Session 10 2) UCM Utrecht 2) Reciept of honoraia or consultation fees Vissing, John Speaker 1) UCB Pharma, Edgewise Therapeutics, Sanofi/Genzyme, 1) Received research and travel support, and/or speaker honararia Scientific Session 02 Fulcrum Therapeutics, Alexion Pharmaceuticals, Genethon Wolfe, Gil Speaker 1) NIDS/NCATS of the National Institutes of Health, MG 1) Receipt of grants/research supports Scientific Session 07 Foundation of America, Muscular Dystrophy Association.
Load more

Recommended publications
  • ALEXION PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 ALEXION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-27756 13-3648318 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 121 Seaport Boulevard, Boston, Massachusetts 02210 (Address of principal executive offices, including zip code) (475) 230-2596 (Registrant’s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Trading Name of each exchange Title of each class Symbol on which registered Common Stock, par value $0.0001 per share ALXN The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    [Show full text]
  • 1976 3M Medical Solutions Division 2019 Electrocore, Inc. 2019 Optinose 1985 Abbott Laboratories, Inc
    CURRENT SUSTAINING MEMBER COMPANIES MEMBER FOR OVER: 10 Years 25 Years 50 Years Member Since (alphabetical order) 1976 3M Medical Solutions Division 2019 electroCore, Inc. 2019 Optinose 1985 Abbott Laboratories, Inc. 2010 Endo Pharmaceuticals 2018 Organogenesis 2013 AbbVie Inc. 2017 Exelixis 2004 Otsuka America Pharmaceutical, Inc. 2021 Adaptive Biotechnologies 2016 Express Scripts Federal Pharmacy 2018 Pacira BioSciences, Inc. 2017 ACADIA Pharmaceuticals, Inc. 2010 Federal Practitioner 2018 Paratek Pharmaceuticals 2020 AcelRx Pharmaceuticals, Inc. 2018 Foundation Medicine, Inc. 1990 Pfizer Pharmaceuticals 2020 Acorda Therapeutics 2021 Frontier Technology Inc. (FTI) 2017 Pharmacyclics, LLC 2019 Aimmune 2020 Fresenius Medical Care North America 2020 RedHill BioPharma 2003 Alcon Laboratories, Inc. 1989 Genentech Inc. 2019 Red One Medical 2019 Alexion Pharmaceuticals, Inc. 2006 Gilead Sciences 2020 Regeneron 2017 Alkermes, Inc. 1983 GLAXOSMITHKLINE 2009 Regenesis Biomedical, Inc. 2019 Alnylam Pharmaceuticals 2013 Golden State Medical Supply, Inc. 2011 Remund Group, LLC 2019 Altarum Institute 2020 GRAIL 2018 Rigel Pharmaceuticals 2020 Amarin Corporation 2019 Greenwich Biosciences 2000 Sanofi 1994 AmerisourceBergen 2013 Gulf Coast Pharmaceuticals Plus, LLC 2020 Seattle Genetics 1992 Amgen 2008 Heritage Health Solutions, Inc. 2004 Siemens Medical Solutions 2020 Amneal Pharmaceutical 2017 Hill-Rom Company 2019 SK Life Science, Inc. 2019 Aptive Resources LLC 2020 Immunomedics 2002 Smith & Nephew, Inc. 2020 The Arbinger Institute 2019 ImmunoVation, LLC 2019 Sobi Inc. 2011 Arbor Pharmaceuticals, LLC 2019 Incyte Corporation 2013 Stryker Orthopaedics 2010 Argentum Medical, LLC 2019 Indivior 2018 Sun Pharmaceutical 2019 ASM Research, LLC 2015 Intercept Pharmaceuticals 1999 Sunovion Pharmaceuticals, Inc. 1986 Astellas Pharma US, Inc. 2019 Ipsen Biopharmaceuticals, Inc. 2016 Taiho Oncology, Inc. 1995 AstraZeneca 2018 IT Cadre 2015 Takeda Oncology 2020 Baudax Bio, Inc.
    [Show full text]
  • Pharma: Strategic Realignment for a 112/113 Better Future Prism / 2 / 2020
    Pharma: Strategic realignment for a 112/113 better future Prism / 2 / 2020 Pharma: Strategic realignment for a better future ... and how the industry will be forced to overcome its hesitation to innovate in operations Ben van der Schaaf, Aurelien Guichard The life sciences sector faces significant impact from Amid the search for COVID-19 – and although the race for treatments and vaccines effective COVID-19 treatments and vaccines, is dominating the headlines, the effect on the industry will the pandemic will have not solely be positive. long-term side effects for the global pharmaceutical In the short term, some companies industry. As our article explains, companies are laying people off and reducing will need to focus on operations, whereas others are change in three areas reallocating resources to focus on (portfolio reprioritization, COVID-19, or even ramping up accelerated R&D and technology efforts in other areas. Stock-market transformation) if they performance has been as diverse are to position (Figure 1). themselves successfully for the future. Organizations need to consider major strategic questions now, to ensure their success in the longer term. The industry is clearly in the middle of the efforts to combat COVID-19: - More than 20 companies are trying to find a treatment with either new or approved drugs1. - More than 15 companies globally are mobilizing resources to develop new vaccines2. - Globally, by the end of May, more than 1,300 clinical trials related to COVID-19 were recruiting patients3. 1. Marketwatch.com, 6 May 2020 2. Drugtargetreview.com, 9 April 2020 3. clintrials.gov, 31 May 2020 Pharma: Strategic realignment for a 114/115 better future Prism / 2 / 2020 2.
    [Show full text]
  • ASN Kidney Week 2020 Reimagined: Disclosures Page 1
    10/14/2020 ASN Kidney Week 2020 Reimagined: Disclosures Page 1 Last Name First Name Nothing Employer Consultancy Ownership Interest Research Funding Honoraria Patents or Inventions Scientific Advisor or Membership Speakers Bureau Other Interests or Relationships to Disclose Abdel-Kader Khaled Vanderbilt University Medical Center BMC Nephrology; CJASN NKF Education committee; NIDDK Health IT work group Abudayyeh Ala University of Texas MD Anderson Cancer Center Adler Sharon Retrophin; Bristol Myers Squibb; Bayer; Retrophin; Bayer; ChemoCentryx; Omeros; Zyversa Bayer; Zyversa; Retrophin; AstraZeneca; Morphosys Retrophin; Bayer Pharmaceuticals; Zyversa; KDIGO; KRN; NephCure Kidney International AstraZeneca; ChemoCentryx; Omeros; Zyversa; Therapeutics; Calliditas; Morphosys AstraZeneca; Morphosys Foundation; Karger Publishers Morphosys; Karger Afkarian Maryam University of California, Davis Afrouzian Marjan University of Texas Medical Branch Alexion Pharmaceuticals; Banff Foundation Afshinnia Farsad Agarwal Anupam University of Alabama at Birmingham Dynamed - review content related to AKI for Goldilocks Therapeutics Genzyme/Sanofi Fabry Fellowship Award Univ Southern California, Vanderbilt, Emory, Akebia Editorial Board of AJP Renal, Kidney Int and My wife, Lisa Curtis, will be President-elect Dynamed and review updated materials prepared by Lab Investigation; invited to serve on for Women in Nephrology (2018-2019). Dynamed editorial team for AKI topics. Akebia - Advisory board of Goldilocks Therapeutics, Expert Panel to review new therapeutics
    [Show full text]
  • Is an Inspiration Every
    Every Day Is An Inspiration 2018 ANNUAL REPORT RACHEL LIVING WITH gMG AIRA LIVING WITH HPP RUTHIE AND HER SON LIVING WITH PNH MAUREEN (FAR LEFT) AND LAUREN (FAR RIGHT) WITH THEIR PARENTS AND BROTHER ETHAN LIVING WITH LAL-D LIVING WITH aHUS Every Day Builds A Tomorrow People with rare and devastating diseases are our inspiration and our Guiding Star. While their diseases are rare, their special life moments should not be. Together, we help patients and their families live their lives fully so they can celebrate the moments that matter most. p.1 p.2 With your support, we are achieving our mission to transform the lives of people affected by rare TO OUR SHAREHOLDERS and devastating diseases by developing and delivering valued innovative therapies. t’s a privilege to report on a year of tremendous progress for Alexion and, • Double-digit underlying volume growth in our base business, serving most importantly, for the patients we serve through our unwavering more patients than ever before with paroxysmal nocturnal hemoglobinuria mission to transform the lives of people living with rare and devastating (PNH), atypical hemolytic uremic syndrome (aHUS), gMG, Idiseases by developing and delivering valued innovative therapies. hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D), exceeding our financial ambitions; and 2018 was a year of transformation for Alexion. When I joined Alexion in 2017, I saw a remarkable opportunity to create more value for patients and • A new Boston headquarters with a strong talent base and a culture where shareholders. We outlined ambitious goals for 2018, which we exceeded, and employees feel empowered, valued and safe to speak up, and where new in the majority of cases far surpassed, through the hard work of our more and diverse ideas are welcome.
    [Show full text]
  • Schedule of Investments Health Care Fund
    SCHEDULE OF INVESTMENTS December 31, 2020 HEALTH CARE FUND SHARES VALUE SHARES VALUE COMMON STOCKS† - 99.5% Dentsply Sirona, Inc. 2,228 $ 116,658 Repligen Corp.* 571 109,421 PHARMACEUTICALS - 31.9% Penumbra, Inc.* 527 92,225 Johnson & Johnson 4,485 $ 705,849 Quidel Corp.* 503 90,364 Merck & Company, Inc. 6,248 511,086 Tandem Diabetes Care, Inc.* 941 90,035 Pfizer, Inc. 13,634 501,868 Hill-Rom Holdings, Inc. 891 87,291 AbbVie, Inc. 4,543 486,782 Haemonetics Corp.* 710 84,312 Bristol-Myers Squibb Co. 6,569 407,475 Nevro Corp.* 459 79,453 Eli Lilly & Co. 2,391 403,696 iRhythm Technologies, Inc.* 332 78,754 CVS Health Corp. 4,915 335,695 Cigna Corp. 1,514 315,185 Total Healthcare-Products 6,434,517 Zoetis, Inc. 1,844 305,182 BIOTECHNOLOGY - 16.9% Becton Dickinson and Co. 1,171 293,008 Amgen, Inc. 1,729 397,532 DexCom, Inc.* 560 207,043 Gilead Sciences, Inc. 5,148 299,923 McKesson Corp. 1,078 187,486 Vertex Pharmaceuticals, Inc.* 1,124 265,646 Viatris, Inc.* 9,039 169,391 Illumina, Inc.* 684 253,080 AstraZeneca plc ADR 3,193 159,618 Regeneron Pharmaceuticals, Inc.* 507 244,937 AmerisourceBergen Corp. — Class A 1,609 157,296 Biogen, Inc.* 849 207,886 Jazz Pharmaceuticals plc* 945 155,972 Moderna, Inc.* 1,869 195,254 ,1 Canopy Growth Corp.* 6,273 154,567 Alexion Pharmaceuticals, Inc.* 1,124 175,614 Horizon Therapeutics plc* 1,986 145,276 Seagen, Inc.* 995 174,264 Novartis AG ADR 1,512 142,778 Exact Sciences Corp.* 1,170 155,013 Cardinal Health, Inc.
    [Show full text]
  • Current Sustaining Member Companies
    CURRENT SUSTAINING MEMBER COMPANIES MEMBER FOR OVER: 10 Years 25 Years 50 Years Member Since (alphabetical order) 1976 3M Medical Solutions Division 2018 Coherus Biosciences 2019 Ipsen Biopharmaceuticals, Inc. 2011 Remund Group, LLC 1985 Abbott Laboratories, Inc. 2017 Cook Medical, LLC 2018 IT Cadre 2018 Rigel Pharmaceuticals 2013 AbbVie Inc. 2020 D2 Pharma Consulting, LLC 1989 J & J Health Care Systems, Inc. 2000 Sanofi 2021 Adaptive Biotechnologies 2007 Daiichi Sankyo, Inc. 2014 Jazz Pharmaceuticals Inc. 2020 Seattle Genetics 2017 ACADIA Pharmaceuticals, Inc. 2020 Deciphera Pharmaceuticals, LLC 2007 Karl Storz Endoscopy America 2004 Siemens Medical Solutions 2020 AcelRx Pharmaceuticals, Inc. 2009 Deloitte 2020 Lipogems 2019 SK Life Science, Inc. 2020 Acorda Therapeutics 2020 Dexcom, Inc. 2010 LLC Federal Solutions 2002 Smith & Nephew, Inc. 2019 Aimmune 2020 Drip Drop Hydration 2014 Lovell Government Services LLC 2019 Sobi Inc. 2003 Alcon Laboratories, Inc. 2017 Eagle Pharmaceuticals, Inc. 2014 Mallinckrodt Pharmaceuticals 2013 Stryker Orthopaedics 2019 Alexion Pharmaceuticals, Inc. 2005 Eisai, Inc. 2020 MannKind Corporation 2018 Sun Pharmaceutical 2017 Alkermes, Inc. 2019 electroCore, Inc. 1999 Marketing Assessment, Inc. 1999 Sunovion Pharmaceuticals, Inc. 2019 Alnylam Pharmaceuticals 2010 Endo Pharmaceuticals 2009 Masimo Corporation 2016 Taiho Oncology, Inc. 2019 Altarum Institute 2017 Exelixis 2019 Medical Strategies International, LLC 2015 Takeda Oncology 2020 Amarin Corporation 2016 Express Scripts Federal Pharmacy 2016 Melling Medical 2000 Takeda Pharmaceutical USA, Inc. 1994 AmerisourceBergen 2010 Federal Practitioner 1954 Merck & Co., Inc. 2020 Telemynd 1992 Amgen 2018 Foundation Medicine, Inc. 2002 MerzNorth America 2020 TerSera Therapeutics 2020 Amneal Pharmaceutical 2021 Frontier Technology Inc. (FTI) 2018 Mitsubishi Tanabe Pharma America 1990 Teva 2019 Aptive Resources LLC 2020 Fresenius Medical Care North America 2014 Nationwide Pharmaceutical LLC 2019 The Coalition for Government Procurement 2011 Arbor Pharmaceuticals, LLC 1989 Genentech Inc.
    [Show full text]
  • VERTEX PHARMACEUTICALS INCORPORATED (Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12 VERTEX PHARMACEUTICALS INCORPORATED (Name of Registrant as Specified In Its Charter) Payment of Filing Fee (Check the appropriate box): No fee required. Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: Fee paid previously with preliminary materials. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: Dear Shareholders: 2019 was a remarkable year for Vertex as all parts of our business - research, development, commercial and business development - performed at exceptional levels.
    [Show full text]
  • Current Sustaining Member Companies
    CURRENT SUSTAINING MEMBER COMPANIES MEMBER FOR OVER: 10 Years 25 Years 50 Years Member Since (alphabetical order) 1976 3M Medical Solutions Division 2018 Coherus Biosciences 2019 Ipsen Biopharmaceuticals, Inc. 2011 Remund Group, LLC 1985 Abbott Laboratories, Inc. 2017 Cook Medical, LLC 2018 IT Cadre 2018 Rigel Pharmaceuticals 2013 AbbVie Inc. 2020 D2 Pharma Consulting, LLC 1989 J & J Health Care Systems, Inc. 2000 Sanofi 2021 Adaptive Biotechnologies 2007 Daiichi Sankyo, Inc. 2014 Jazz Pharmaceuticals Inc. 2020 Seattle Genetics 2017 ACADIA Pharmaceuticals, Inc. 2020 Deciphera Pharmaceuticals, LLC 2007 Karl Storz Endoscopy America 2004 Siemens Medical Solutions 2020 AcelRx Pharmaceuticals, Inc. 2009 Deloitte 2021 Lantheus Holdings 2019 SK Life Science, Inc. 2020 Acorda Therapeutics 2020 Dexcom, Inc. 2020 Lipogems 2002 Smith & Nephew, Inc. 2019 Aimmune 2020 Drip Drop Hydration 2010 LLC Federal Solutions 2019 Sobi Inc. 2003 Alcon Laboratories, Inc. 2017 Eagle Pharmaceuticals, Inc. 2014 Lovell Government Services LLC 2013 Stryker Orthopaedics 2019 Alexion Pharmaceuticals, Inc. 2005 Eisai, Inc. 2014 Mallinckrodt Pharmaceuticals 2018 Sun Pharmaceutical 2017 Alkermes, Inc. 2019 electroCore, Inc. 2020 MannKind Corporation 1999 Sunovion Pharmaceuticals, Inc. 2019 Alnylam Pharmaceuticals 2010 Endo Pharmaceuticals 1999 Marketing Assessment, Inc. 2016 Taiho Oncology, Inc. 2019 Altarum Institute 2017 Exelixis 2009 Masimo Corporation 2015 Takeda Oncology 2020 Amarin Corporation 2016 Express Scripts Federal Pharmacy 2019 Medical Strategies International, LLC 2000 Takeda Pharmaceutical USA, Inc. 1994 AmerisourceBergen 2010 Federal Practitioner 2016 Melling Medical 2020 Telemynd 1992 Amgen 2021 Ferring Pharmaceuticals Inc. 1954 Merck & Co., Inc. 2020 TerSera Therapeutics 2020 Amneal Pharmaceutical 2018 Foundation Medicine, Inc. 2002 MerzNorth America 1990 Teva 2019 Aptive Resources LLC 2021 Frontier Technology Inc.
    [Show full text]
  • ALEXION PHARMACEUTICALS, INC. ------(Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 16, 2014 ALEXION PHARMACEUTICALS, INC. ----------------------------------------------------------- (Exact name of registrant as specified in its charter) Delaware 000-27756 13-3648318 ------------------ ------------------ --------------- (State or other jurisdiction of (Commission (I.R.S. Employer of incorporation or organization) File Number) Identification No.) 352 Knotter Drive, Cheshire, Connecticut 06410 --------------------------------------------------------------- (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (203) 272-2596 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On July 16, 2014, the Board of Directors of Alexion Pharmaceuticals, Inc. increased the number of directors from 8 to 11 and appointed David R. Brennan, M. Michele Burns and Christopher J. Coughlin to Alexion’s Board of Directors, effective immediately. Mr. Brennan is expected to join the Compensation, Pharmaceutical Compliance and Quality, and Risk and Strategy Committees.
    [Show full text]
  • Vertex Pharmaceuticals Incorporated
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12 VERTEX PHARMACEUTICALS INCORPORATED (Name of Registrant as Specified In Its Charter) Payment of Filing Fee (Check the appropriate box): No fee required. Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: Fee paid previously with preliminary materials. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: Dear Shareholders: Since 2012 we have executed on our strategy of investing in scientific innovation to create transformative medicines for people with serious diseases - a strategy we believe maximizes benefits for patients and generates long-term value for shareholders.
    [Show full text]
  • How Will Deals Done Now Deliver What the Health Ecosystem Needs Next? 2020 EY M&A Firepower Report Ey.Com/Lifesciences Contents
    How will deals done now deliver what the health ecosystem needs next? 2020 EY M&A Firepower report ey.com/lifesciences Contents 3 Executive summary 8 A look back at 2019 18 Betting on the business model 24 What’s ahead in 2020 30 The innovation agenda 35 Methodology 38 Acknowledgments 39 Contacts 2 | Firepower 2020 Executive summary Context Trigger Key question 2019 life sciences dealmaking A majority of life sciences companies How will deals done now reached unprecedented levels, as face capital allocation and growth deliver what the health ecosystem companies sought to increase pressures, while simultaneously needs next? therapy area focus. positioning themselves for a technology and data-driven future. To deliver what the health ecosystem needs next, life sciences companies must use dealmaking to focus their business models, close near-term growth gaps and access future innovation using models that extend beyond M&A. Sixty percent of small/ Acute growth gaps and the Companies took advantage mid-cap biopharmas ability to act opportunistically Life sciences dealmaking of US$1.4 trillion in are trading below their in a volatile market created exceeded US$350 billion, Firepower to close growth 12-month average share significant M&A opportunities breaking a 2014 record. gaps and acquire prices, suggesting more in 2019. near-term revenue. deals in 2020. The companies most likely Recent deals underscore The need to create In January 2019, EY to succeed are those that how companies have used therapeutically focused researchers predicted the stop work in areas where focused dealmaking to businesses also drove 2019 growing importance of they do not have — and improve their five-year M&A totals.
    [Show full text]